Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
56.33 USD | +1.20% | -2.63% | -9.85% |
Apr. 18 | Citigroup Adjusts CRISPR Therapeutics' Price Target to $89 From $88, Keeps Buy Rating | MT |
Apr. 17 | Crispr Therapeutics Insider Sold Shares Worth $1,173,232, According to a Recent SEC Filing | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.85% | 4.72B | |
+3.25% | 42.11B | |
+48.83% | 40.08B | |
+8.47% | 40B | |
-10.82% | 26.87B | |
+8.16% | 24.58B | |
-23.21% | 18.44B | |
+1.16% | 11.94B | |
+33.51% | 11.66B | |
+7.07% | 11.01B |
- Stock Market
- Equities
- CRSP Stock
- News CRISPR Therapeutics AG
- CRISPR Therapeutics : JMP Securities Starts CRISPR Therapeutics at Market Outperform With $160 Price Target